Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis

BACKGROUND: multiple sclerosis (MS) patients are treated with immunomodulatory treatments that can influence their ability to develop a protective antibody response to the SARS-CoV-2 vaccine. Vaccine efficacy is important for treatment decision and for patients’ reassurance. The main objective is to...

Descripción completa

Detalles Bibliográficos
Autores principales: Brill, Livnat, Rechtman, Ariel, Zveik, Omri, Haham, Nitzan, Levin, Netta, Shifrin, Alla, Rozenberg, Ayal, Vaknin-Dembinsky, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539216/
https://www.ncbi.nlm.nih.gov/pubmed/35158452
http://dx.doi.org/10.1016/j.msard.2021.103343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539216/
https://www.ncbi.nlm.nih.gov/pubmed/35158452
http://dx.doi.org/10.1016/j.msard.2021.103343

Ejemplares similares